MEF2D and acute lymphoblastic leukemia: Since a proportion of pre-BCR + BCP-ALL cases without MEF2D fusion but disposing related signature gene set,33 it is reasonable to speculate that CUDC-907 may exhibit comparable efficacy in pre-BCR + BCP-ALL patients, given the analogous transcriptomic expression profiles and shared pathogenic mechanisms.